Newron says EPO will issue safinamide patent for PD
Italian R&D firm Newron Pharmaceuticals says that it has received a written confirmation from the European Patent Office that it intends to grant the patent Methods for treatment of Parkinson's disease. The application was filed by Newron in Europe and in all other major countries in 2004.
The patent relates to methods for treating PD through the administration of Newron's compound safinamide in combination with levodopa.
Safinamide, which is being developed by German drugmaker Merck Serono and Newron as an add-on therapy to dopamine agonists as well as to levodopa for patients with PD, is currently in phase III clinical trials. Merck Serono, a division of Merck KGaA, has exclusive worldwide rights to develop, manufacture and commercialize safinamide in PD, Alzheimer's disease and other therapeutic applications, under an agreement signed with Newron in 2006.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze